Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630666 | 0.97 | HSD11B1 (0.79) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| Water SCHEMBL6544001 | 0.95 | HSD11B1 (0.77) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2479508 | 0.95 | HSD11B1 (0.79) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL6543280 | 0.95 | HSD11B1 (0.79) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| Water SCHEMBL6544000 | 0.95 | HSD11B1 (0.77) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL6161721 | 0.95 | HSD11B1 (0.77) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL18390858 | 0.88 | MEN1 (0.69) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11081075 | 0.88 | MEN1 (0.74) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11088640 | 0.87 | HSD11B1 (0.73) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL373284 | 0.87 | SMN1; SMN2 (0.74) | HSD11B1MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | disclosed |
| US-6710042-B2 | PIPERIDINE DERIVATIVES; TREATMENT OF PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-03-23 | — | — | US | disclosed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | disclosed |
| EP-1019373-A1 | NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-6028082-A | FOR TRATING PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | HSD11B1 1296/4885MEN1 2993/4885KMT2A 2018/4885 |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | HSD11B1 1296/4885MEN1 2993/4885KMT2A 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.